Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Milne

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Food and Drug Law Journal|February 11, 2014
FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?Andrew Wilson, Christopher-Paul Milne
Nature Reviews. Drug Discovery|March 2, 2012
Market watch: industry perspectives on personalized medicineRachael Zuckerman, Christopher-Paul Milne
Clinical Therapeutics|February 18, 2014
The pediatric studies initiative: after 15 years have we reached the limits of the law?Christopher-Paul Milne, Jonathan Davis
Journal of AOAC International|April 2, 2008
Determination of pesticide residues (> 0.5 microg/L) in soft drinks and sports drinks by gas chromatography with mass spectrometry: collaborative studyKathleen D Miller, Paul Milne
Education for Primary Care : an Official Publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors|January 30, 2013
The Medical Leadership Competency Framework: challenges raised for GP educators by a pilot study of culture in general practiceStephen George Willcocks, Paul Milne
Clinical Therapeutics|September 25, 2017
The Use of Social Media in Orphan Drug DevelopmentChristopher-Paul Milne, Wendi Ni
Food and Drug Law Journal|November 27, 2008
Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?Laura B Faden, Christopher-Paul Milne
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
Science Translational Medicine|April 7, 2010
Translational medicine: an engine of change for bringing new technology to community healthChristopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|December 26, 2008
The economics of pediatric formulation development for off-patent drugsChristopher-Paul Milne, Jon B Bruss
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Food and Drug Law Journal|February 11, 2014
FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?Andrew Wilson, Christopher-Paul Milne
Nature Reviews. Drug Discovery|March 2, 2012
Market watch: industry perspectives on personalized medicineRachael Zuckerman, Christopher-Paul Milne
Clinical Therapeutics|February 18, 2014
The pediatric studies initiative: after 15 years have we reached the limits of the law?Christopher-Paul Milne, Jonathan Davis
Journal of AOAC International|April 2, 2008
Determination of pesticide residues (> 0.5 microg/L) in soft drinks and sports drinks by gas chromatography with mass spectrometry: collaborative studyKathleen D Miller, Paul Milne
Education for Primary Care : an Official Publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors|January 30, 2013
The Medical Leadership Competency Framework: challenges raised for GP educators by a pilot study of culture in general practiceStephen George Willcocks, Paul Milne
Clinical Therapeutics|September 25, 2017
The Use of Social Media in Orphan Drug DevelopmentChristopher-Paul Milne, Wendi Ni
Food and Drug Law Journal|November 27, 2008
Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?Laura B Faden, Christopher-Paul Milne
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
Science Translational Medicine|April 7, 2010
Translational medicine: an engine of change for bringing new technology to community healthChristopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|December 26, 2008
The economics of pediatric formulation development for off-patent drugsChristopher-Paul Milne, Jon B Bruss
Pageof 7